2009
DOI: 10.5222/terh.2009.40222
|View full text |Cite
|
Sign up to set email alerts
|

The Association Of Non-Hodgkin Lymphoma With Renal Cell Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The use of other receptor tyrosine kinase inhibitors such as nilotinib or sorafenib may also be considered (16). Follow-ups should be done at 3-6 month intervals, with contrast-enhanced abdominal MSCT.…”
Section: Discussionmentioning
confidence: 99%
“…The use of other receptor tyrosine kinase inhibitors such as nilotinib or sorafenib may also be considered (16). Follow-ups should be done at 3-6 month intervals, with contrast-enhanced abdominal MSCT.…”
Section: Discussionmentioning
confidence: 99%